NCT06177925View on ClinicalTrials.gov

A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

December 10, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions
Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsSmall Cell Lung Carcinoma
Interventions
DRUG

Adebrelimab

Adebrelimab intravenous infusion will be administered during the induction phase (Cycles 1-2 ) and maintenance phase.

DRUG

Carboplatin/Cisplatin

Carboplatin/Cisplatin intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).

DRUG

Etoposide

Etoposide intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).

RADIATION

Radiation therapy

IMRT for thoracic of 45--55Gy in 15-22 fractions，SBRT for metastases during the concurrent chemoradiotherapy phase

Trial Locations (1)

Unknown

RECRUITING

Nanfang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
collaborator

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

lead

Nanfang Hospital, Southern Medical University

OTHER